Module 3: Current Treatment of Chronic Myelogenous Leukemia – Imatinib and Allogeneic SCT
This learning activity has been designated for 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Learning Objectives
After completing this educational activity, the learner should be better able to:
- Discuss the improvement in prognosis for patients with chronic myelogenous leukemia (CML) treated with targeted biologic therapies as compared with older therapeutic interventions
- Review the key data from the IRIS trial
- State the criteria for suboptimal response or treatment failure
- Discuss treatment options available to patients who experience treatment failure while on imatinib
Target Audience
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who manage and treat chronic myelogenous leukemia in the hematology/oncology and transplant patient settings.
Release Date: November 30, 2008
Expiration date: November 30, 2009
(*Please check this box to proceed - required)
Start the Module